Bristol Myers posts quarterly loss, lays out $1.5 bln cost-saving plan
Today the company reported a first-quarter loss as charges related to its acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue.
If you are not happy with the results below please do another search
Today the company reported a first-quarter loss as charges related to its acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue.
Following 10 years of leadership in the market access and reimbursement marketing space, Navisync, an NPG Health company, is proud to unveil new branding—including a new logo and new agency cornerstones.
The company announced today that its drug, Rinvoq, for treating a type of inflammatory skin condition, was found to be more effective than Regeneron Pharmaceuticals and Sanofi’s Dupixent in a late-stage head-to-head study.
By not only tackling high costs but also elevating patient experiences by enhancing efficiency and outcomes, this technology stands ready to revolutionize many aspects of the industry, says GlobalData.
Yesterday that FDA approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
Sen. Bernie Sanders (I-Vt.) on Wednesday launched an investigation into the exorbitant prices of Novo Nordisk’s Ozempic and Wegovy blockbusters, and has asked the Danish drugmaker to justify their price tags.
Mammoth’s CRISPR-based gene editing platform and Regeneron’s delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver.
The New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous forecast of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year.
New Ogilvy survey shows 7 in 10 people either follow or seek out health content or learn about health/medical issues from social media – and a vast majority of those who engage take some form of action.
Biogen beat market estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the impact of fierce competition for its older drugs, sending its shares up nearly 7% before the bell.